End-of-day quote
27/08/2026
5-day change
1st Jan Change
85.00 NOK
-1.62%
-1.62%
-15.00%
Market Cap
513M
54.91M
47.28M
44.39M
40.52M
76.12M
5.22B
76.67M
526M
205M
2.65B
206M
202M
8.77B
P/E 2023 *
-
P/E 2024
3.26x Enterprise Value
264M
28.29M
24.35M
22.87M
20.87M
39.21M
2.69B
39.5M
271M
105M
1.36B
106M
104M
4.52B
EV / Sales 2023
-1.24x
EV / Sales 2024
0.4x Free-Float
6.26%
Yield 2023 *
-
Yield 2024
32.5%
Day Week Month
Close Mountain
06-16
Norda ASA announces Annual dividend, payable on June 25, 2026
CI
12/05/25
Norda ASA announces Annual dividend, payable on May 22, 2025
CI
05/05/25
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2024
CI
31/10/23
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2022
CI
15/06/22
Norda ASA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
20/06/21
Norda Asa Reports Earnings Results for the Full Year Ended December 31, 2020
CI
22/05/13
Norda ASA Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2013
CI
09/04/13
Norda ASA Reports Unaudited Net Debt Results as of December 31, 2012
CI
09/04/13
Norda ASA Appoints Scient Frode Westvold as CEO
CI
28/02/13
Norda ASA Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2012
CI
31/10/12
Norda ASA Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2012
CI
12/10/12
Norda ASA Obtains NOK 35 Million Line of Credit from a Norwegian Bank
CI
29/08/12
Norda ASA Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2012
CI
1 day -1.62%
1 week -1.62%
Current month -1.62%
1 month -1.62%
3 months -1.62%
6 months -0.12%
Current year -15.00%
1 week
85
85
1 month
85
85
Current year
81
86.4
1 year
81
100
3 years
41
100
5 years
41
100
10 years
8
100
Manager
Title Age Since
Chief Executive Officer
-
07/04/2013
Director
Title Age Since
Chairman
54
30/01/2014
Director/Board Member
68
19/06/2013
Director/Board Member
-
-
2023 2024 Net sales
86.92M
9.3M
8.01M
7.52M
6.86M
12.89M
885M
12.99M
89.1M
34.67M
449M
34.92M
34.16M
1.49B
372M
39.79M
34.26M
32.17M
29.36M
55.16M
3.79B
55.56M
381M
148M
1.92B
149M
146M
6.36B
Net income
31.17M
3.34M
2.87M
2.7M
2.46M
4.62M
317M
4.66M
31.95M
12.43M
161M
12.52M
12.25M
533M
126M
13.48M
11.6M
10.89M
9.95M
18.68M
1.28B
18.82M
129M
50.23M
650M
50.6M
49.5M
2.15B
Net Debt
-311M
-33.3M
-28.67M
-26.92M
-24.58M
-46.17M
-3.17B
-46.5M
-319M
-124M
-1.61B
-125M
-122M
-5.32B
-249M
-26.62M
-22.92M
-21.52M
-19.65M
-36.91M
-2.53B
-37.17M
-255M
-99.23M
-1.28B
-99.96M
-97.79M
-4.25B
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-6pm CET
DAILY FREE LIMIT REACHED
To continue browsing, Sign up!
Personal watchlists and screeners
Access the "Discovery" Stock Screener (covering 30,000 companies)
Create your free account
Become a member and join over 1 million active investors
Already have an account?
Log in
Select your edition
All financial news and data tailored to specific country editions